CoChat

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

Imbimbo, Bruno P., Ippati, Stefania, Watling, Mark, Balducci, Claudia · 2022 · Alzheimer's & Dementia
Cited by 75

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

Abstract

Introduction: Primary tauopathies are neurological disorders in which tau protein deposition is the predominant pathological feature. Alzheimer's disease is a secondary tauopathy with tau forming hyperphosphorylated insoluble aggregates. Tau pathology can propagate from region to region in the brain, while alterations in tau processing may impair tau physiological functions. Methods: We reviewed literature on tau biology and anti‐tau drugs using PubMed, meeting abstracts, and ClnicalTrials.gov. Results: The past 15 years have seen >30 drugs interfering with tau aggregation, processing, and accumulation reaching the clinic. Initial results with tau aggregation inhibitors and anti‐tau monoclonal antibodies have not shown clinical efficacy. Discussion: The reasons for these clinical failures are unclear but could be linked to the clearing of physiological forms of tau by non‐specific drugs. Research is now concentrating efforts on developing reliable translational animal models and selective compounds targeting specific tau epitopes, neurotoxic tau aggregates, and post‐translational tau modifications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12453

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 111 references

Cited by

Metadata

Authors
Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2021-09-17
Volume
18
Issue
5
Pages
1008-1037
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W3200084131
Cited by
75
References
111
FWCI
6.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.